News Summary

OpenAI is reportedly in discussions with the US Food and Drug Administration (FDA) regarding the use of artificial intelligence to enhance the drug evaluation process. The collaboration aims to leverage a project called cderGPT to potentially modernize and accelerate the lengthy drug approval timelines. The discussions include exploring how AI can be integrated into the Center for Drug Evaluation’s workflows to make certain steps more efficient. This initiative highlights the potential of AI to transform the traditionally slow processes of drug development, despite ongoing concerns about the reliability of AI models.